Presentations & Publications Corporate Presentation September 2020 Corporate Presentation September 21, 2020 Synlogic’s Virtual R&D Event May 27, 2020 Publications Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Developing a new class of engineered live bacterial therapeutics to treat human diseases An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Presentations and Posters A Phase 1/2a Oral Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Subjects with Phenylketonuria September 4, 2019 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019 A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria June 23, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer June 23, 2019 The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease June 23, 2019 22nd Annual Meeting of the American Society of Gene & Cell Therapy April 30, 2019 Genetically engineered E. coli Nissle attenuates hyperammonemia in two experimental models of hepatic encephalopathy November 12, 2018 The Liver Meeting, AASLD, November 2018 November 12, 2018 Development of Synthetic Biotic Medicines in Oncology Presentation November 10, 2018 Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting November 10, 2018 Email Alerts Contact IR RSS Feeds Print Page Email Page
Corporate Presentation September 2020 Corporate Presentation September 21, 2020 Synlogic’s Virtual R&D Event May 27, 2020 Publications Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity Developing a new class of engineered live bacterial therapeutics to treat human diseases An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018) Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates Presentations and Posters A Phase 1/2a Oral Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Subjects with Phenylketonuria September 4, 2019 Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019 A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria June 23, 2019 Engineering Synthetic Biotic Medicines for the Treatment of Cancer June 23, 2019 The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease June 23, 2019 22nd Annual Meeting of the American Society of Gene & Cell Therapy April 30, 2019 Genetically engineered E. coli Nissle attenuates hyperammonemia in two experimental models of hepatic encephalopathy November 12, 2018 The Liver Meeting, AASLD, November 2018 November 12, 2018 Development of Synthetic Biotic Medicines in Oncology Presentation November 10, 2018 Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting November 10, 2018
An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans
Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat. Biotechnol. 36, 857–864 (2018)
Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates
A Phase 1/2a Oral Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Subjects with Phenylketonuria September 4, 2019
Simulations to Estimate Effects of Reduced Phenylalanine Intake on Blood Phenylalanine in Phenylketonuria September 4, 2019
A Synthetic Live Bacterial Therapeutic Organism for the Treatment of the Human Metabolic Disease Phenylketonuria June 23, 2019
The development of leucine consuming strains as therapeutics for Maple Syrup Urine Disease June 23, 2019
Genetically engineered E. coli Nissle attenuates hyperammonemia in two experimental models of hepatic encephalopathy November 12, 2018